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Abstract 
Autotaxin produces the bioactive lipid lysophosphatidic acid (LPA), and is a drug target of 
considerable interest for numerous pathologies. We report the expedient, structure-guided 
evolution of weak physiological allosteric inhibitors (bile salts) into potent competitive 
Autotaxin inhibitors that do not interact with the catalytic site. Functional data confirms that 
our lead compound attenuates LPA mediated signalling in cells, and reduces LPA synthesis 
in vivo, providing a promising natural product derived scaffold for drug discovery. 
 
  
Introduction 
Autotaxin (ATX, ENPP2) is responsible for the production of the bioactive lipid 
lysophosphatidic acid (LPA) from lysophospholipids which exist extracellularly, primarily 
derived from lysophosphatidylcholine (LPC).1 The product of this process, LPA, is an agonist 
of six G protein-coupled receptors that drives a range of signaling pathways.2 This action 
produces a broad range of biological outcomes, and the pathophysiology of ATX has been 
associated with pulmonary fibrosis, tumor progression, cardiovascular disease, neuropathic 
pain, and cholestatic pruritus; these functions make the ATX-LPA signaling pathway an 
attractive prospect from the point of view of therapeutic intervention.3 
The catalytic domain of the enzyme consists of an active site containing to zinc ions in 
proximity to a catalytic threonine. The endogenous ligand (LPC) binds in a shallow 
hydrophilic groove that is capable of accommodating both nucleotides as well as the glycerol 
motif of lysophospholipids. There also exists a relatively deep hydrophobic pocket which is 
responsible for binding of the lysophospholipid acyl chain. The catalytic domain in 
conjunction with the first of two somatomedin-ȕ 60% GRPDLQV constitutes a tunnel 
adjacent to the active site.4±5 Recently, we reported that ATX produced in mammalian cells 
contains steroids bound within the tunnel region. During that study, we determined the 
structures of natural endogenous steroids bound to the ATX tunnel, including that of 
tauroursodeoxycholic acid (TUDCA, 1, Figure 1), a micromolar inhibitor of LPA production. 
We demonstrated that binding of bile salts, allosterically modulates ATX activity through 
non-competitive inhibition, likely having physiologically important implications for the function 
of the ATX-mediated signaling through LPA receptors in a number of pathophysiological 
contexts.6 
The majority of small molecule inhibitors of ATX developed to date emulate the lipid-like 
structure of the native ligand and bind in the orthosteric site (e.g. 3, Figure 1). By contrast, a 
recent series of indole-based ATX inhibitors7 and the lead compound of an independent 
discovery program8 are reported to occupy the hydrophobic pocket and tunnel, without 
interacting with the hydrophilic groove or the active site, acting as allosteric inhibitors, similar 
to natural bile salts.  
In this manuscript, we formulate a design hypothesis based on structural knowledge of the 
binding mode of the partial non-competitive allosteric inhibitor bile salts, and competitive 
orthosteric inhibitors.9 Specifically, we used the structure of compound 1 bound to ATX 
(Figure 1) which we recently determined binding in the allosteric tunnel region,6 and the 
structure of a compound from the represented by compound 2 (PF-8380),10 which we had 
determined in complex with ATX, showing the binding of this chemotype in the orthosteric 
site. 
From consideration of these binding modes we inferred that the tunnel-binding steroid 
skeleton could be merged with the lipophilic pocket-ELQGLQJ³WDLO´RIcompound 2. While the 
³WDLO´of compound 2 is in isolation ineffective,11 as is the steroid group alone,6 we reasoned 
the hybridized structures may be potent inhibitors of ATX. 
  
Results and Discussion 
We crystallized an alcohol analogue (3, Figure 2) of compound 2, which, owing to its 
significantly higher aqueous solubility, proved more amenable to co-crystallization compared 
to the parent compound, 2. We determined the crystal structure of 3 bound to ATX (Figure 1 
A-C) to 2.1 Å resolution, showing that the 3,5-dichlorobenzyl moiety of 3 binds in the lipid 
binding pocket, consistent with a recent report of the binding mode of this series.12 
Superposing this structure of 3, with that of 1 in complex with ATX6 (Figure 1 D-F) enabled 
the design of a highly chemically tractable hybrid series through the union of the two binding 
motifs (Figure 2). 
 
Figure 1. Crystal structure of 3 and 1 binding to the hydrophobic pocket and the tunnel of 
ATX, respectively. (A-C) show that 3 binds to the hydrophobic pocket. Compound 3 is 
racemic and the (R) enantiomer is resolved through co-crystallography; (D-F) show that 1 
binds to the tunnel. 
  
 Figure 2. Overarching design hypothesis 
These compounds could be rapidly prepared through HATU-mediated amide bond formation 
between ursodeoxycholic acid (UDCA) and appropriate amine fragments (Scheme 1). 
Compound 11 was accessed through reduction of the amide to give the corresponding 
amine derivative. The requisite amine components could be prepared through carbamate 
formation on the mono-protected diamine, followed by deprotection to furnish the free amine 
as represented by the example shown in Scheme 2.   
 
Scheme 1. Conditions (a) amine (0.9 equiv), HATU (1.0 equiv), DIPEA (4.0 equiv), DMF, rt; 
(b) BH3·THF (10 equiv), THF, 60 °C. 
 
Scheme 2. D µ-carbonyldiimidazole (1.1 equiv), 3,5-dichlorobenzylalcohol (1.1 equiv), 
amine (1.0 equiv), DMF, rt; (b) Trifluoroacetic acid/CH2Cl2 (1:1). 
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To our delight, the first hybrid compound prepared (4, Table 1) showed approximately an 80-
IROG LQFUHDVH LQSRWHQF\UHODWLYH WRWKHSURJHQLWRUELOHDFLGȝ0FRPSDUHGWRȝ0, 
determined through measurement of inhibition of LPC hydrolysis), confirming that the 
concept of maintaining the steroid moiety while also targeting the hydrophobic pocket of ATX 
had indeed increased inhibitor potency. In agreement with this hypothesis, compounds 
without chlorine substituents (9-10) or lacking a hydrophobic anchor entirely (8) in this initial 
set of analogues, results in no detectable inhibitory activity. These findings are consistent 
with SAR previously established for the hydrophobic pocket, all of which indicate a degree of 
lipophilicity in this region is required for adequate levels of ATX-inhibitory activity.10±13  
In this initial survey of SAR, we also sought to examine the length and nature of the linker (5-
7). While the piperazine unit in 4 was optimal, linear systems exhibit only slightly lower 
potency (5-6); however, a very short spacer (7) resulted in no detectable inhibitory activity. 
Compound 11, lacking the amide carbonyl of 4, had five-fold lower potency.  
  
Table 1. Evaluation of hybrid 
compounds. 
 
Compound 
IC50 
ȝ0 MW LogDb Compound 
IC50 
ȝ0 MW LogDb 
 
10.3 500 -0.2 
 
2.5 692 6.4 
 
0.129 664 6.0 
 
0.100 708 5.2 
 
0.202 638 5.7 
 
2.10a 675 5.4 
 
0.563 652 5.8 
 
1.00 650 5.8 
 
> 30 551 6.1 
 
0.208 650 5.8 
 
> 30 435 0.6 
 
0.020 664 5.9 
 
> 30 569 4.5 
 
0.717 664 5.9 
 
> 30 595 4.8 
 
0.313 664 5.9 
 
0.814 650 6.6 
 
0.500 664 5.9 
[a] Epimeric mixture; [b] calculated at pH 7.4 using JChem for Excel.14 
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 Figure 3. Crystal structure of ATX bound to 5, 11 and 17. The view and representation is 
similar to Figure 1. 
 Figure 4. Two-dimensional projection depicting the interactions between the three ligands 5 
(A), 11 (B), 17 (C) and ATX, highlighting hydrogen bonds with Trp275, Tyr82 and Trp260 of 
ATX (arrows).  
 
To further rationalize the SAR data obtained and confirm our proposed binding mode 
hypothesis, we determined the crystal structure of ATX bound to 5 and 11 to 2.4 Å and 2.1 Å 
resolution, respectively (Figure 3 A-D and Figure 4 A and B). These structures fully support 
our original design hypothesis and demonstrate that the hydrophobic anchor, the 3,5-
dichlorobenzyl group, occupies essentially the same position in the hydrophobic pocket in 
the structures of 3, 5, and 11. Notably, the steroid moiety also remains in a similar, albeit not 
identical binding orientation between structures, when comparing the structures of 1, 5, and 
11, and is held in position by several interactions including two hydrogen bonds, with the 
Tyr82 and Trp260 side chains. The piperazine linker unit, however, adopts a significantly 
different conformation in 11 compared to 3, projecting towards the tunnel, instead of the 
catalytic site; the linear linker in 5 follows a similar vector to that of the piperazine in 11. 
Interestingly, the linker region in both structures does not exhibit well defined electron 
density compared to the other groups, suggesting a certain degree of structural flexibility in 
the region, with the linker potentially adopting several conformations. Accordingly, these 
structures suggest that the bile salt steroid moiety and the dichlorobenzyl group act as 
anchors in the tunnel and the pocket, respectively, and optimization of binding should 
subsequently focus on the linker region to provide a conformation which may lead to optimal 
binding. Based on this, the 3,5-dichlorobenzyl group was retained in subsequent analogues 
prepared, and our focus turned to tuning the spacer region of our nascent series. 
Several isosteric cores were evaluated (12-20, Table 1) with a range of ATX inhibitory 
activity noted. Aminomethyl piperidine systems were tolerated with a preference for the 
exocyclic carbamate (cf. 12-13), and more constrained systems such as 14 led to a 10-fold 
reduction in activity. Other isosteres such as azetidinyl and 3-amino pyrrolidine (15-20) 
showed comparable levels of potency relative to the progenitor compound 4. A notable 
exception is evidenced by compound 17, displaying an IC50 of 20 nM against ATX mediated 
production of LPA, which compares favorably to 2 (IC50 = 3 nM10). Additionally, This 
represents an over 500-fold improvement in activity compared to the parent bile acid, and 
demonstrates the utility of a structure based design approach in expediently optimizing a 
weak endogenous modulator of ATX activity towards a highly potent lead candidate. 
The crystal structure of 17 bound to ATX (Figure 3 E and F, Figure 4 C) was determined to 
1.95 Å resolution, and illustrates that similar to the structures of 5 and 11, the 3,5-
dichlorobenzyl and the steroid groups again act as anchors in the pocket and the tunnel, 
respectively, making several contacts with ATX, and occupying essentially the same 
positions as in complexes of 5 and 11. The two hydrogen bonds between ATX and the 
steroid moiety of hybrid inhibitors remain the same in the complex of ATX with 17 (Figure 4 
C) as for the complexes with 5 and 11; however, the positioning of the new linker allows the 
formation of an additional hydrogen bond between the urethane carbonyl and the main chain 
amide of Trp275. This observation could account in part for the increased potency of 17. In 
addition, the electron density for the linker region is better defined in this structure, indicating 
a more restricted spatial distribution of the linker. The linker of 17 also has a better fit to the 
ATX surface (compare Figure 3 E to 3 A, C). Collectively, these structural observations 
account for the superior activity of 17. 
To further characterize the potency and mechanism of inhibition, we examined inhibition of 
LPC hydrolysis by 17 in greater depth, based on measurement of a single LPA species, 
(18:1, referring to an 18 carbon chain with a single degree of unsaturation). As anticipated, 
17 was shown to be a competitive inhibitor of LPC hydrolysis (Figure 5) with a Ki of 0.006 
ȝ07KLVFRQWUDVWVZLWKWKHSURJHQLWRUVWHURLG1 which is a weak non-competitive inhibitor of 
LPC hydrolysis. Accordingly, by targeting the hydrophobic pocket, we have switched the 
mechanism of action in this emerging lead series compared to the endogenous modulator 1. 
 
Figure 5. 17 acts as a competitive inhibitor of LPC hydrolysis. (A) ATX lysoPLD activity with 
no inhibitor (blue symbols) and with four concentrations of 17 as a function of LPC (18:1) 
substrate concentrations; the lines represent the non-linear regression fit of all data (B) a 
simulated Lineweaver-Burk plot, fitting the velocity for each experiment separately, 
graphically demonstrating that 17 acts as a competitive inhibitor of LPC hydrolysis with a Ki 
of 6 ± 2 nM.  
Having developed a novel tool compound with known mechanism of action, we 
subsequently sought to demonstrate that 17 inhibits LPA-mediated signaling in cancer cells, 
by examining its ability to block phosphorylation of the AKT kinase; consistently, 
FRQFHQWUDWLRQVRIDERYHȝ0RI17 decreases the level of pAKT, as detected by Western 
blot analysis (Figure 6 A), suggesting that compound 17 is a viable tool in a physiologically 
relevant context. 
Lastly, in order to examine inhibition of ATX in vivo, 17, and 2 as a positive control, were 
administered to mice (10 mg/kg, i.p.) and the levels of eight abundant LPA species were 
summed and determined by mass spectrometry.15 The in vivo activity of 17 was similar to 
that of 2, reducing LPA levels to about half to that of control mice injected with vehicle alone 
(Figure 6 B). Although determination of in vivo half-life was not possible in this experiment, 
the data indicates that compound 17 must have sufficient degree of stability in order to be 
able to modulate LPA levels 8 hours following i.p. administration.  This highly encouraging 
data indicates robust target engagement in an in vivo setting, thus validating our emerging 
lead series as promising tools to further prosecute the biology of Autotaxin in a variety of 
disease states. 
 
Figure 6. (A) Western-blot showing inhibition of ATX by 17 decreases Ser473 
phosphorylation of AKT in BJEH cells. (B) Graphical depiction of Western-blot using 
densitometry. (C) LPA levels measured for the injection of control, 2 and 17, showing the 
levels of LPA in the individual animals (circles) and the median value (horizontal line); 
6WXGHQW¶V XQSDLUHG WZR WDLOHG 7-test suggests the difference of 2 and 17 to the control is 
significant (p < 0.01). 
In summary, we report the development of an endogenous steroid modulator of Autotaxin 
function towards a highly potent hybrid lead series with significant levels of activity in vivo. 
The optimization trajectory was significantly expedited through application of a structure-
based design approach, leading to the rapid identification of compound 17 which could be 
differentiated from the progenitor steroid both in terms of significantly enhanced potency and 
mechanism of action (competitive vs non-competitive inhibition of LPA hydrolysis). The 
structural data generated confirmed the original design hypothesis, and support the 
observed mechanism of action for the series lead, compound 17. Inhibition of ATX activity by 
our lead compound in cells and in a pilot experiment in mice, suggest that these new entities 
will serve as valuable tools in further understanding the pathophysiological roles of Autotaxin. 
  
Experimental 
 
Chemistry. General. All reagents and solvents were obtained from commercial suppliers 
and were used without further purification unless otherwise stated. Purification was carried 
out according to standard laboratory methods. Reactions were carried out using 
conventional glassware room temperature was generally 18 °C. Reactions were carried out 
at elevated temperatures using a temperature-regulated hotplate/stirrer. Thin layer 
chromatography was carried out using Merck silica plates coated with fluorescent indicator 
UV254. These were analyzed under 254 nm UV light or developed using potassium 
permanganate solution. Normal phase flash chromatography was carried out using ZEOprep 
60 HYD 40-63 µm silica gel. Fourier Transformed Infra-Red (FTIR) spectra were obtained on 
a Shimadzu IRAffinity-1 machine. 1H and 13C, NMR spectra were obtained on a Bruker AV 
400 at 400 MHz and 101 MHz, respectively and a Bruker AVIIIHD500 at 500 MHz and 126 
MHz, respectively. Chemical shifts are reported in ppm and coupling constants are reported 
in Hz with CDCl3 referenced at 7.26 (1H) and 77.1 ppm (13C) and DMSO-d6 referenced at 
2.50 (1H) and 39.52 ppm (13C). Compound purity was determined by LCMS and NMR 
analysis, and all compounds were η 95% purity. High-resolution mass spectra were 
obtained through analysis at the EPSRC UK National Mass Spectrometry Facility at 
Swansea University or in the School of Chemistry at the University of Glasgow, UK.  
 
General Procedure A: Carbamate Formation. For example, for the preparation of 1-(tert-
butyl) 4-(3,5-dichlorobenzyl) piperazine-1,4-dicarboxylate, 21.11 To a round bottom flask was 
added (3,5-GLFKORURSKHQ\OPHWKDQRO  J  PPRO  HTXLY ¶-
carbonyldiimidazole (0.96 g, 5.91 mmol, 1.10 equiv) in DMF (5 mL) and stirred for 30 min at 
room temperature. To the reaction mixture was added tert-butyl piperazine-1-carboxylate 
(1.00 g, 5.37 mmol, 1.00 equiv) and stirred for 30 min at room temperature. The reaction 
was diluted with H2O (10 mL) and the precipitate filtered under vacuum with H2O, and dried 
in a dessicator to afford the desired product as a white solid (1.87 g, 90 %).  Xmax (neat): 
2847, 1698, 1678, 1418 cm-1. 1H NMR (CDCl3, 400 MHz): G 7.34 (t, J = 1.9 Hz, 1H), 7.25 (d, 
J = 1.91 Hz, 2H), 5.10 (s, 2H), 3.55-3.48 (m, 4H), 3.48-3.42 (m, 4H), 1.49 (s, 9H). 13C NMR 
(CDCl3, 101 MHz): G 154.8, 154.7, 140.0, 153.3, 128.4, 126.3, 80.4, 65.8, 43.9, 28.5. 1 × C 
not observed. HRMS: exact mass calculated for [M+NH4]+ (C17H26Cl2N3O4) requires m/z 
406.1295, found m/z 406.1293. 
 
General Procedure B: N-Benzyl Carbamate Formation. For example, for the preparation 
of benzyl tert-butyl ethane-1,2-diyldicarbamate, 22.11 To a round bottom flask was added 
tert-butyl 3-methylpiperazine-1-carboxylate (100 mg, 0.50 mmol, 1.00 equiv), N-
(benzyloxycarbonyloxy)succinimide (137 mg, 0.55 mmol, 1.10 equiv) and NaHCO3 (66.4 mg, 
0.75 mmol, 1.40 equiv), in THF:H2O (1 mL:1 mL)  and stirred for 16  h at room temperature. 
The reaction mixture was diluted with H2O (20 mL) and the organics were extracted with 
ethyl acetate (2 × 20 mL), dried with a hydrophobic frit and concentrated in vacuo to afford 
the desired product as a clear oil (154 mg, 89%). Xmax (neat): 3314, 2977, 2931, 1689, 1546 
cm-1. 1H NMR (CDCl3, 400 MHz): G  7.39-7.28 (m, 5H), 5.29 (s, 1H), 5.09 (s, 2H), 4.94 (s, 
1H), 3.32-3.15 (m, 4H), 1.42 (s, 9H). 13C NMR (CDCl3, 101 MHz): G 156.3, 155.9, 136.0, 
128.0, 127.63, 127.60, 79.1, 66.2, 41.0, 40.1, 27.9. HRMS: exact mass calculated for [M+H]+ 
(C15H23N2O4) requires 295.1652 m/z, found 295.1654 m/z. 
 
General Procedure C: N-Boc deprotection. For example, for the preparation of 3,5-
dichlorobenzyl piperazine-1-carboxylate, 23.11 To a round bottom flask was added 1-(tert-
butyl) 4-(3,5-dichlorobenzyl)piperazine-1,4-dicarboxylate (1.87g, 4.80 mmol), a mixture of 
trifluoroacetic acid:CH2Cl2 (1 mL:1mL) and the reaction stirred at room temperature for 2 h. 
The reaction mixture was concentrated in vacuo and purified by strong cation exchange 
eluting with 2 M NH3 in MeOH to afford the desired product as a white solid (0.53 g, 60%). 
Consistent with previously reported spectral analysis. Xmax (neat): 2918, 2849, 2494, 1670, 
1425, 1128 cm-1. 1H NMR (CDCl3, 400 MHz,): G 7.26 (t, J = 1.7 Hz, 1H), 7.20 (d, J = 1.8 Hz, 
2H), 5.04 (s, 2H), 3.51-3.45 (m, 4H), 2.88-2.81 (m, 4H), 2.02 (s, 1H). 13C NMR (CDCl3, 101 
MHz): G 154.7, 140.1, 135.1, 128.2, 126.1, 65.6, 45.5, 44.4. HRMS: exact mass calculated 
for [M+H]+ (C12H15Cl2N2O2) requires m/z 289.0505, found m/z 289.0503. 
 
General Procedure D: HATU amidation.  For example, for the preparation of, 3,5-
dichlorobenzyl-4-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-
1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)piperazine-1-carboxylate, 4. To a round 
bottom flask was added ursodeoxycholic acid (100 mg, 0.26 mmol, 1.1 equiv) in DMF (1 mL), 
N,N-diisopropylethylamine (180 µL, 1.02 mmol, 4.0 equiv) and then 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide 
hexafluorophosphate (HATU, 97 mg, 0.26 mmol, 1.1 equiv). After stirring at room 
temperature for 15 min 3,5-dichlorobenzyl piperazine-1-carboxylate (67 mg, 0.23 mmol, 1.0 
equiv) was added and stirred for 16 h at room temperature. The reaction mixture was diluted 
with H2O (20 mL) and the resulting precipitate filtered under vacuum. The crude material 
was purified by column chromatography on silica (0-10% MeOH in ethyl acetate) to afford 
the desired product as a clear solid (87 mg, 51%). Xmax (neat): 3496, 2931, 2866, 1708, 1637, 
1421, 1231 cm-1. 1H NMR (CDCl3, 500 MHz): G 7.32-7.30 (m, 1H), 7.24-7.21 (m, 2H), 5.08 (s, 
2H), 3.65-3.44 (m, 9H), 2.42-2.32 (m, 1H), 2.28-2.18 (m, 1H), 2.02-1.96 (m, 1H), 1.96-1.85 
(m, 1H), 1.85-1.74 (m, 4H), 1.74-1.63 (m, 3H), 1.63-1.55 (m, 2H), 1.53-1.39 (m, 6H), 1.38-
1.22 (m, 5H), 1.17-0.98 (m, 3H), 0.96-0.91 (m, 6H), 0.67 (s, 3H), 2 × H not observed 
(exchangeable).  13C NMR (CDCl3, 101 MHz): G 172.4, 154.8, 139.9, 135.3, 128.5, 126.4, 
71.54, 71.47, 66.0, 55.9, 55.1, 45.4, 43.9, 42.6, 40.3, 39.3, 37.4, 37.0, 35.6, 35.1, 34.2, 31.5, 
30.5, 28.8, 27.0, 23.5, 21.3, 18.8, 12.3. 2 × C not observed. HRMS: exact mass calculated 
for [M+Na]+ (C36H52Cl2N2NaO5) requires 685.3145 m/z, found 685.3119 m/z. 
 
3,5-Dichlorobenzyl (2-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamido)ethyl)carbamate (5). Prepared according to General Procedure D with 
ursodeoxycholic acid (176 mg, 0.45 mmol, 1.1 equiv), N,N-diisopropylethylamine (286 µL, 
1.64  mmol, 4.0 equiv), HATU (171 mg, 0.45 mmol, 1.1 equiv), 3,5-dichlorobenzyl (2-
aminoethyl)carbamate (107 mg, 0.41 mmol, 1.0 equiv) and DMF (2 mL). The crude material 
was subjected to the purification procedure outlined in the General Procedure (silica gel, 0-
10% MeOH in CH2Cl2) to give the desired product as a clear solid (134 mg, 51 %). Xmax 
(neat): 3329, 2933, 2864, 1706, 1652, 1574 cm-1. 1H NMR (CDCl3, 400 MHz): G 7.30-7.27 (m, 
1H), 7.23-7.19 (m, 2H), 6.34 (br. s, 1H), 5.73 (br. s, 1H), 5.01 (s, 2H), 3.65-3.50 (m, 2H), 
3.42-3.25 (m, 4H), 2.27-2.12 (m, 1H), 2.11-2.00 (m, 1H), 2.00-1.93 (m, 1H), 1.88-1.71 (m, 
5H), 1.70-1.61 (m, 2H), 1.60-1.53 (m, 2H), 1.50-1.35 (m, 5H), 1.35-1.16 (m, 6H), 1.14-0.98 
(m, 3H), 0.97-0.87 (m, 6H), 0.64 (s, 3H), 2 × H not observed (exchangeable). 13C NMR 
(CDCl3, 101 MHz): G 175.0, 156.9, 140.1, 135.2, 128.2, 126.1, 71.4, 65.1, 56.01, 55.95, 55.1, 
43.8, 42.6, 41.2, 40.3, 39.9, 39.4, 37.5, 37.2, 35.6, 35.1, 34.2, 33.6, 32.0, 30.4, 28.8, 27.0, 
23.5, 21.3, 18.6, 12.2. 1 × C not observed. HRMS: exact mass calculated for [M+Na]+ 
(C34H50Cl2N2NaO5) requires 659.2989 m/z, found 659.2965 m/z. 
 
3,5-Dichlorobenzyl (3-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamido)propyl)carbamate (6). Prepared according to General Procedure D with 
ursodeoxycholic acid (156 mg, 0.39 mmol, 1.1 equiv), N,N-diisopropylethylamine (314 µL, 
1.8  mmol, 4.0 equiv), HATU (151 mg, 0.39 mmol, 1.1 equiv), 3,5-dichlorobenzyl (3-
aminopropyl)carbamate (100 mg, 0.36 mmol, 1.0 equiv) and DMF (1 mL). The crude 
material was subjected to the purification outlined in the General Procedure (silica gel, 0-
10% MeOH in CH2Cl2) to give the desired product as a clear solid (39 mg, 16 %). Xmax 
(neat): 3813, 2933, 2866, 1708, 1654, 1574, 1542 cm-1. 1H NMR (CDCl3, 400 MHz): G 7.31-
7.28 (m, 1H), 7.25-7.21 (m, 2H), 5.92 (s, 1H), 5.33 (s, 1H), 5.03 (s, 2H), 3.62-3.55 (m, 2H), 
3.51-3.46 (m, 2H), 3.35-3.31 (m, 2H), 3.26-3.18 (m, 2H), 2.29-2.20 (m, 1H), 2.16-2.04 (m, 
1H), 2.03-1.96 (m, 1H), 1.95-1.86 (m, 1H), 1.84-1.74 (m, 4H), 1.71-1.55 (m, 7H), 1.53-1.39 
(m, 6H), 1.37-1.21 (m, 4H), 1.14 (td, J = 3.1, 12.6 Hz, 1H), 1.10-0.98 (m, 2H), 0.97-0.90 (m, 
6H), 0.67 (s, 3H).  13C NMR (CDCl3, 101 MHz): G 174.4, 156.6, 140.3, 135.2, 128.2, 126.1, 
71.6, 71.5, 65.1, 55.9, 55.1, 43.9, 42.6, 40.3, 39.3, 37.7, 37.5, 37.0, 36.0, 35.6, 35.1, 34.2, 
33.8, 32.0, 30.5, 30.2, 28.8, 27.0, 23.5, 21.3, 18.6, 12.3. 1 × C not observed. HRMS: exact 
mass calculated for [M+Na]+ (C35H52Cl2N2NaO5) requires 673.3145 m/z, found 673.3113 m/z. 
 
(4R)-N-(3,5-Dichlorobenzyl)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamide (7). 
Prepared according to General Procedure D with ursodeoxycholic acid (100 mg, 0.26 mmol, 
1.0 equiv), N,N-diisopropylethylamine (180 µL, 1.02 mmol, 4.0 equiv), HATU (97 mg, 0.26 
mmol, 1.0 equiv), 3,5-dichlorobenzylamine (35 µL, 0.26 mmol, 1.0 equiv) and DMF (1 mL).  
The crude material was subjected to the purification outlined in the General Procedure (silica 
gel, 0-10% MeOH in CH2Cl2) to afford the desired product as a white solid (14 mg, 10%). 
Xmax (neat): 3296, 2931, 2866, 1654, 1574, 1434 cm-1. 1H NMR (CDCl3, 400 MHz): G 7.28-
7.25 (m, 1H), 7.15 (d, J = 1.9 Hz, 2H), 5.80 (s, 1H), 4.39 (d, J = 6.1 Hz, 2H), 3.64-3.54 (m, 
2H), 2.35-2.25 (m, 1H), 2.18-2.09 (m, 1H), 1.99 (dt, J = 3.0, 12.4 Hz, 1H), 1.94-1.85 (m, 1H), 
1.85-1.74 (m, 3H), 1.70-1.63 (m, 2H), 1.62-1.55 (m, 3H), 1.53-1.39 (m, 6H), 1.38-1.20 (m, 
6H), 1.17-0.97 (m, 3H), 0.96-0.91 (m, 6H), 0.67 (s, 3H). 13C NMR (CDCl3, 101 MHz): G 173.6, 
142.1, 135.4, 127.8, 126.2, 71.6, 71.5, 55.9, 55.1, 43.9, 42.7, 42.6, 40.3, 39.3, 37.5, 37.0, 
35.5, 35.1, 34.2, 33.7, 31.9, 30.5, 28.8, 27.0, 23.5, 21.3, 18.6, 12.3. 1 × C not observed. 
HRMS: exact mass calculated for [M+Na]+ (C31H45Cl2NNaO3) requires 572.2669 m/z, found 
572.2650 m/z. 
 
(4R)-N-(2-Aminoethyl)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamide (8). 
Prepared according to General Procedure C, using tert-butyl (2-((4R)-4-((3R,7S,10S,13R)-
3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamido)ethyl)carbamate (936 mg, 1.75 mmol, 1.0 equiv), trifluoroacetic acid (2 mL), 
CH2Cl2 (4 mL), diluted with 1 M NaOH (100 mL), the organics were extracted with ethyl 
acetate (100 mL), washed with brine (100 mL), dried with a hydrophobic frit and 
concentrated in vacuo to afford the desired product as a white solid (605 mg, 63 %). Xmax 
(neat): 3283, 2935, 2669, 1715, 1654, 1157 cm-1. 1H NMR (CDCl3, 500 MHz): G 9.36 (s, 1H), 
7.89 (s, 1H), 4.42 (d, J = 4.6 Hz, 1H), 3.85 (d, J = 6.8 Hz, 1H), 3.21 (t, J = 5.4 Hz, 2H), 3.17 
(t, J = 5.5 Hz, 2H), 2.13-2.03 (m, 1H), 1.99-1.90 (m, 2H), 1.86-1.80 (m, 1H), 1.86-1.80 (m, 
1H), 1.80-1.71 (m, 1H), 1.70-1.60 (m, 3H), 1.51-1.43 (m, 3H), 1.42-1.26 (m, 7H), 1.23-1.06 
(m, 3H), 1.03-0.92 (m, 2H), 0.89-0.85 (m, 6H), 0.61 (s, 3H). 13C NMR (CDCl3, 101 MHz): G 
173.0, 69.7, 69.4, 55.9, 54.7, 43.1, 43.0, 42.2, 39.8, 39.2, 38.7, 37.7, 37.30, 37.26, 34.9, 
34.8, 33.7, 32.4, 31.5, 30.2, 28.1, 26.7, 23.3, 20.8, 18.4, 12.0. HRMS: exact mass calculated 
for [M+H]+ (C26H47N2O3) requires 435.3581 m/z, found 435.3576 m/z. 
 
Benzyl (2-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanamido)ethyl)carbamate (9). Prepared according 
to General Procedure D with ursodeoxycholic acid (445 mg, 1.13 mmol, 1.1 equiv), N,N-
diisopropylethylamine (720 µL, 4.12 mmol, 4.0 equiv), HATU (430 mg, 0.13 mmol, 1.1 equiv), 
benzyl (2-aminoethyl)carbamate (200 mg, 1.03 mmol, 1.0 equiv) and DMF (5 mL). The 
crude material was subjected to the purification outlined in the General Procedure (silica gel, 
0-10% MeOH in CH2Cl2) to afford the desired product as a clear solid (399 mg, 68 %). Xmax 
(neat): 3298, 2933, 2866, 1706, 1652, 1527 cm-1. 1H NMR (CDCl3, 500 MHz): G 7.39-7.28 (m, 
5H), 6.10 (s, 1H), 5.29 (s, 1H), 5.09 (s, 2H), 3.63-3.52 (m, 2H), 3.41-3.28 (m, 4H), 2.21-2.16 
(m, 1H), 2.08-2.01 (m, 1H), 2.01-1.96 (m, 1H), 1.91-1.84 (m, 1H), 1.82-1.75 (m, 3H), 1.73-
1.64 (m, 4H), 1.61-1.54 (m, 3H), 1.52-1.39 (m, 5H), 1.34-1.20 (m, 6H), 1.16-1.09 (m, 1H), 
1.06-0.99 (m, 2H),  0.95-0.88 (m, 6H), 0.67 (s, 3H). 13C NMR (101 MHz, CDCl3): G 174.6, 
157.4, 136.5, 128.7, 128.3, 128.2, 71.6, 71.5, 67.0, 55.9, 55.1, 43.9, 42.6, 41.2, 40.3, 39.4, 
37.5, 37.0, 35.6, 35.1, 34.2, 33.7, 31.9, 30.5, 28.8, 27.0, 23.5, 21.3, 18.6, 12.3. 2 × C not 
observed. HRMS: exact mass calculated for [M+Na]+ (C34H52N2NaO5) requires 591.3768 m/z, 
found 591.3746 m/z. 
 
Benzyl-4-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanoyl)piperazine-1-carboxylate (10). Prepared 
according to General Procedure D with ursodeoxycholic acid (500 mg, 1.27 mmol, 1.1 equiv), 
N,N-diisopropylethylamine (450µL, 2.57 mmol, 2.0 equiv), HATU (243 mg, 1.27 mmol, 1.1 
equiv), benzylpiperazine-1-carboxylate (223 µL, 1.16 mmol, 1.0 equiv) and  DMF (5 mL). 
The crude material was subjected to the purification outlined in the General Procedure (silica 
gel, 0-10% MeOH in CH2Cl2) to afford the desired product as a clear solid (258 mg, 37%). 
Xmax (neat): 3374, 2929, 2866, 1702, 1630 cm-1. 1H NMR (CDCl3, 500 MHz): G 7.39-7.30 (m, 
5H), 5.15 (s, 2H), 3.63-3.54 (m, 4H), 3.56-3.40 (m, 7H), 2.41-2.33 (m, 1H), 2.26-2.17 (m, 1H), 
1.99 (d, J = 12.5 Hz, 1H), 1.95-1.85 (m, 1H), 1.84-1.73 (m, 4H), 1.71-1.63 (m, 3H), 1.62-1.55 
(m, 2H), 1.52-1.39 (m, 6H), 1.39-1.21 (m, 5H), 1.19-0.97 (m, 3H), 0.97-0.91 (m, 6H), 0.67 (s, 
3H). 13C NMR (CDCl3, 101 MHz): G 172.4, 155.3, 136.5, 128.7, 128.4, 128.2, 71.6, 71.5, 
67.6, 55.9, 55.1, 45.5, 43.9, 42.6, 41.4, 40.3, 39.3, 37.4, 37.0, 35.6, 35.1, 34.2, 31.5, 30.5, 
28.8, 27.0, 23.5, 21.3, 18.8, 12.3. 2 × aliphatic C not observed. HRMS: exact mass 
calculated for [M+Na]+ (C36H54N2NaO5) requires 617.3925 m/z, found 617.3915 m/z. 
 
3,5-Dichlorobenzyl-4-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentyl)piperazine-1-
carboxylate (11). To a round bottom flask at 0 qC was added 3,5-dichlorobenzyl 4-((4R)-4-
((3R,7S,10S,13R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanoyl)piperazine-1-carboxylate (92 mg, 0.14 mmol, 1.0 
equiv), THF (5 mL), BH3.THF (1 M, 700 µL, 0.70 mmol, 5.0 equiv) and the reaction stirred at 
70 qC for 16 h. The reaction mixture was cooled to room temperature, quenched with 1 M 
HCl (20 mL) and stirred for 1 h. The organics were extracted with ethyl acetate (20 mL), 
washed with brine (20 mL), dried with a hydrophobic frit and concentrated in vacuo. The 
crude material was purified by column chromatography on silica (0-100% MeOH in CH2Cl2) 
to afford the desired product as a white solid (4 mg, 4%). Xmax (neat): 3381, 2929, 2866, 
1708, 1635 cm-1. 1H NMR (CDCl3, 500 MHz): G 7.33-7.31 (m, 1H), 7.23 (d, J = 1.7 Hz, 2H), 
5.08 (s, 2H), 3.66-3.43 (m, 12H), 2.43-2.34 (m, 1H), 2.29-2.18 (m, 1H), 2.03-1.97 (m, 1H), 
1.96-1.86 (m, 1H), 1.85-1.74 (m, 4H), 1.71-1.62 (m, 2H), 1.62-1.53 (m, 4H), 1.52-1.41 (m, 
6H), 1.39-1.32 (m, 2H), 1.29-1.21 (m, 2H), 1.19-1.11 (m, 2H), 1.11-1.01 (m, 2H), 0.99-0.92 
(m, 6H), 0.68 (s, 3H). 13C NMR (CDCl3, 126 MHz): G 172.4, 139.9, 135.3, 128.5, 126.4, 71.6, 
71.5, 66.0, 55.9, 55.1, 51.0, 45.5, 43.9, 42.6, 40.3, 39.3, 37.5, 37.0, 35.7, 35.1, 34.2, 31.5, 
30.5, 28.9, 27.1, 23.5, 21.3, 18.8, 12.3. 3 × C not observed. HRMS: exact mass calculated 
for [M+H]+ (C36H55Cl2N2O4) requires 649.3533 m/z, found 649.3506 m/z. 
 
3,5-Dichlorobenzyl-4-(((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamido)methyl)piperidine-1-carboxylate (12). Prepared according to General 
Procedure D with ursodeoxycholic acid (136 mg, 0.35 mmol, 1.1 equiv), N,N-
diisopropylethylamine (223 µL, 1.28 mmol, 4.0 equiv), HATU (133 mg, 0.35 mmol, 1.1 equiv), 
3,5-dichlorobenzyl 4-(aminomethyl)piperidine-1-carboxylate (100 mg, 0.32 mmol, 1.0 equiv) 
and DMF (2 mL). The crude material was subjected to the purification outlined in the 
General Procedure (silica gel, 0-10% MeOH in CH2Cl2) to afford the desired product as a 
clear solid (80 mg, 36 %). Xmax (neat): 3323, 2931, 2866, 1691, 1654 cm-1. 1H NMR (CDCl3, 
400 MHz): G 7.31-7.29 (m, 1H), 7.23-7.20 (m, 2H), 5.52 (s, 1H), 5.05 (s, 2H), 4.27-4.09 (m, 
2H), 3.65-3.53 (m, 2H), 3.26-3.08 (m, 2H), 2.89-2.79 (m, 2H), 2.30-2.21 (m, 1H), 2.14-2.03 
(m, 1H), 2.02-1.96 (m, 1H), 1.95-1.86 (m, 1H), 1.85-1.75 (m, 3H), 1.74-1.63 (m, 4H), 1.63-
1.55 (m, 4H), 1.55-1.39 (m, 6H), 1.38-1.12 (m, 7H), 1.10-0.98 (m, 2H), 0.97-0.90 (m, 6H), 
0.67 (s, 3H). 13C NMR (CDCl3, 101 MHz): G 173.8, 154.8, 140.4, 135.2, 128.2, 126.2, 71.6, 
71.5, 65.6, 55.9, 55.1, 44.9, 44.0, 43.9, 42.6, 40.3, 39.3, 37.5, 37.0, 36.3, 35.5, 35.1, 34.2, 
33.8, 32.0, 30.5, 29.8, 28.8, 27.0, 23.5, 21.3, 28.6, 12.3. 1 × C not observed. HRMS: exact 
mass calculated for [M+Na]+ (C38H56Cl2N2NaO5) requires 713.3458 m/z, found 713.3425 m/z. 
 
3,5-Dichlorobenzyl ((1-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-4-
hydroxypiperidin-4-yl)methyl)carbamate (13). Prepared according to General Procedure 
D with ursodeoxycholic acid (67 mg, 0.17 mmol, 1.1 equiv), N,N-diisopropylethylamine (131 
µL, 0.75 mmol, 5.0 equiv), HATU (65 mg, 0.17 mmol, 1.1 equiv), 3,5-dichlorobenzyl ((4-
hydroxypiperidin-4-yl)methyl)carbamate (50 mg, 0.15 mmol, 1.0 equiv) and DMF (1 mL). The 
crude material was subjected to the purification outlined in the General Procedure (silica gel, 
0-10% MeOH in CH2Cl2) to afford the desired product as a clear solid (5.1 mg, 3 %). Xmax 
(neat): 3357, 2929, 2866, 1702, 1618, 1574 cm-1. 1H NMR (CDCl3, 400 MHz): G 7.34-7.28 (m, 
1H), 7.25 (d, J = 1.7 Hz, 2H), 5.28 (s, 1H), 5.05 (s, 2H), 4.26 (d, J = 12.9 Hz, 1H), 3.64-3.54 
(m, 3H), 3.43 (t, J = 11.4 Hz, 1H), 3.34-3.25 (m, 1H), 3.22-3.15 (m, 1H), 3.11 (t, J = 11.4 Hz, 
1H), 2.45-2.34 (m, 1H), 2.32-2.19 (m, 1H), 2.04-1.97 (m, 1H), 1.96-1.86 (m, 1H), 1.85-1.73 
(m, 4H), 1.69-1.64 (m, 2H), 1.62-1.54 (m, 6H), 1.53-1.47 (m, 3H), 1.46-1.40 (m, 4H), 1.38-
1.28 (m, 5H), 1.19-0.98 (m, 3H), 0.97-0.90 (m, 6H), 0.70 (s, 3H). 13C NMR (CDCl3, 101 
MHz): G 172.2, 157.3, 139.8, 135.3, 128.4, 126.2, 71.6, 71.5, 70.4, 65.6, 55.9, 55.1, 51.4, 
43.9, 42.6, 41.7, 40.3, 39.3, 37.5, 37.4, 37.0, 35.7, 35.5, 35.1, 34.8, 34.2, 31.7, 30.52, 30.48, 
28.8, 27.1, 23.5, 21.3, 18.8, 12.3. Rotameric mixture observed. HRMS: exact mass 
calculated for [M+Na]+ (C38H56Cl2N2NaO6) requires 729.3408 m/z, found 729.3372  m/z. 
 
2-(3,5-Dichlorobenzyl)-7-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanoyl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one (14). Prepared according to 
General Procedure D with ursodeoxycholic acid (120 mg, 0.31 mmol, 1.1 equiv), N,N-
diisopropylethylamine (244 µL, 1.50 mmol, 5.0 equiv), HATU (117 mg, 0.31 mmol, 1.1 equiv), 
2-(3,5-dichlorobenzyl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one (73 mg, 0.32 mmol, 1.0 
equiv) and DMF (2 mL). The crude material was subjected to the purification outlined in the 
General Procedure (silica gel, 0-10% MeOH in CH2Cl2) to afford the desired product as a 
clear solid as an epimeric mixture (80 mg, 36%). Xmax (neat): 3404, 2931, 2864, 1691, 1635, 
1429 cm-1. 1H NMR (CDCl3, 400 MHz, 323 K): G 7.30-7.27 (m, 1H), 7.16-7.12 (m, 2H), 4.72-
4.57 (m, 1H), 4.38 (d, J = 15.4 Hz, 1H), 4.29 (d, J = 15.5 Hz, 1H),  3.95 (d, J = 12.1 Hz, 1H), 
3.84-3.71 (m, 1H), 3.64-3.53 (m, 3H), 3.35 (t, J = 8.6 Hz, 1H), 3.20-3.04 (m, 1H), 3.01-2.84 
(m, 2H), 2.43-2.32 (m, 1H), 2.32-2.19 (m, 1H), 2.00 (d, J = 12.5 Hz, 1H), 1.95-1.75 (m, 5H), 
1.71-1.65 (m, 2H),  1.63-1.56 (m, 2H), 1.56-1.40 (m, 8H), 1.38-1.02 (m, 8H), 1.00-0.92 (m, 
6H), 0.67 (s, 3H). 13C NMR (CDCl3, 101 MHz): G 172.6, 159.0, 140.5, 135.5, 128.0, 126.5, 
71.51, 71.46, 60.5, 55.8, 55.1, 50.8, 47.3, 46.0, 45.5, 45.3, 43.9, 42.5, 41.2, 40.3, 39.3, 37.4, 
37.0, 35.6, 35.0, 34.2, 31.5, 30.5, 30.4, 28.8, 27.0, 23.5, 21.3, 18.8, 12.3. HRMS: exact 
mass calculated for [M+Na]+ (C37H53Cl2N3NaO4) requires 696.3305 m/z, found 696.3289 m/z. 
 
3,5-Dichlorobenzyl-3-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)azetidine-1-
carboxylate (15). Prepared according to General Procedure D with ursodeoxycholic acid 
(157 mg, 0.40 mmol, 1.1 equiv), N,N-diisopropylethylamine (314 µL, 1.8  mmol, 4.0 equiv), 
HATU (152 mg, 0.40 mmol, 1.1 equiv), 3,5-dichlorobenzyl 3-aminoazetidine-1-carboxylate 
(100 mg, 0.36 mmol, 1.0 equiv) and DMF (1 mL). The crude material was subjected to the 
purification outlined in the General Procedure (silica gel, 0-10% MeOH in CH2Cl2) to afford 
the desired product as a clear solid (108 mg, 46 %). Xmax (neat): 3400, 2933, 2865, 1699, 
1654, 1574, 1419 cm-1. 1H NMR (CDCl3, 500 MHz): G 7.30-7.27 (m, 1H), 7.21-7.17 (m, 2H), 
6.51 (br. s, 1H), 5.00 (s, 2H), 4.69-4.62 (m, 1H), 4.35-4.28 (m, 2H), 3.83 (dd, J = 5.2, 9.3 Hz, 
2H), 3.60-3.51 (m, 2H), 2.31-2.19 (m, 1H), 2.12-2.02 (m, 1H), 2.02-1.94 (m, 1H), 1.93-1.84 
(m, 3H), 1.82-1.72 (m, 4H), 1.69-1.62 (m, 2H), 1.61-1.54 (m, 2H),  1.50-1.45 (m, 2H), 1.44-
1.39 (m, 4H), 1.35-1.18 (m, 5H), 1.16-0.98 (m, 3H), 0.95-0.88 (m, 6H), 0.65 (s, 3H). 13C 
NMR (CDCl3, 101 MHz): G 173.8, 155.7, 140.0, 135.2, 128.3, 126.2, 71.43, 71.38, 65.2, 56.0, 
55.1, 50.8, 43.9, 43.8, 42.6, 40.3, 39.9, 39.4, 37.5, 37.1, 35.6, 35.0, 34.2, 33.4, 31.8, 30.4, 
28.8, 27.0, 23.5, 21.3, 18.6, 12.3. HRMS: exact mass calculated for [M+Na]+ 
(C35H50Cl2N2NaO5) requires 671.2989 m/z, found 671.2957 m/z. 
 
3,5-Dichlorobenzyl (1-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)azetidin-3-
yl)carbamate (16). Prepared according to General Procedure D with ursodeoxycholic acid 
(157 mg, 0.40 mmol, 1.1 equiv), N,N-diisopropylethylamine (314 µL, 1.8 mmol, 4.0 equiv), 
HATU (152 mg, 0.40 mmol, 1.1 equiv), 3,5-dichlorobenzyl azetidin-3-ylcarbamate (100 mg, 
0.36 mmol, 1.0 equiv) and DMF (1 mL). The crude material was subjected to the purification 
outlined in the General Procedure (silica gel, 0-10% MeOH in CH2Cl2) to afford the desired 
product as a clear solid (140 mg, 60 %). Xmax (neat): 3400, 2933, 2865, 1708, 1637, 1438, 
1449 cm-1. 1H NMR (CDCl3, 400 MHz): G 7.33-7.29 (m, 1H), 7.23-7.19 (m, 2H), 5.63 (br. s, 
1H), 5.04 (s, 2H), 4.55-4.46 (m, 1H), 4.41 (t, J = 8.0 Hz, 1H), 4.29 (t, J = 9.1 Hz, 1H), 3.97 
(dd, J = 5.1, 8.5 Hz, 1H), 3.83 (dd, J = 5.2, 10.3 Hz, 1H), 3.64-3.52 (m, 2H), 2.16-2.04 (m, 
1H), 2.03-1.95 (m, 2H), 1.92-1.84 (m, 1H), 1.83-1.74 (m, 4H), 1.73-1.70 (m, 2H), 1.69-1.63 
(m, 2H), 1.62-1.54 (m, 2H), 1.53-1.38 (m, 5H), 1.34-1.20 (m, 5H), 1.16-0.99 (m, 3H), 0.96-
0.88 (m, 6H), 0.66 (s, 3H). 13C NMR (CDCl3, 101 MHz): G 174.1, 169.1, 139.7, 135.3, 128.5, 
126.3, 71.6, 71.5, 65.4, 58.1, 55.9, 55.1, 54.9, 51.0, 43.9, 42.6, 40.9, 40.3, 39.3, 37.5, 37.0, 
35.6, 35.1, 34.2, 31.0, 30.5, 28.8, 28.7, 27.0, 23.5, 21.3, 18.7, 12.3. HRMS: exact mass 
calculated for [M-H]- (C35H49Cl2N2O5) requires 647.3024 m/z, found 647.3021 m/z. 
 
3,5-Dichlorobenzyl ((3R)-3-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamido)cyclopentyl)carbamate (17). Prepared according to General Procedure E 
with ursodeoxycholic acid (149 mg, 0.38 mmol, 1.1 equiv), N,N-diisopropylethylamine (306 
µL, 1.75 mmol, 5.0 equiv), HATU (145 mg, 0.38 mmol, 1.1 equiv), 3,5-dichlorobenzyl ((3R)-
3-aminocyclopentyl)carbamate (100 mg, 0.35 mmol, 1.0 equiv) and DMF (10 mL). The crude 
material was subjected to the purification outlined in the General Procedure (silica gel, 0-
10% MeOH in CH2Cl2) to afford the desired product as a clear solid (82 mg, 35%). Xmax 
(neat): 3301, 2931, 2968, 1697, 1654, 1420 cm-1. 1H NMR (CDCl3, 400 MHz): G 7.29-7.26 (m, 
1H), 7.22-7.18 (m, 2H), 5.03 (s, 2H), 4.50-4.41 (m, 1H), 3.72-3.60 (m, 1H), 3.60-3.42 (m, 4H), 
3.30-3.20 (m, 1H), 2.25-2.12 (m, 2H), 2.08-2.01 (m, 1H), 1.99-1.93 (m, 1H), 1.89-1.71 (m, 
6H), 1.68-1.61 (m, 2H), 1.58-1.53 (m, 2H), 1.49-1.38 (m, 6H), 1.31-1.19 (m, 5H), 1.14-0.97 
(m, 3H), 0.96-0.87 (m, 6H), 0.63 (s, 3H). NH and 2 × OH not observed (exchangeable). 13C 
NMR (CDCl3, 101 MHz): G 173.8, 154.4, 140.2, 135.1, 128.2, 126.2, 71.31, 71.26, 65.4, 56.0, 
55.1, 51.6, 49.4, 48.6, 44.6, 44.2, 43.8, 43.7, 42.6, 40.3, 39.4, 37.4, 37.2, 35.5, 35.0, 34.1, 
33.5, 31.9, 30.9, 30.4, 28.8, 27.0, 23.5, 21.3, 18.6, 12.2. Rotameric mixture observed. 
HRMS: exact mass calculated for [M+NH4]+ (C36H56Cl2N3O5) requires 680.3592 m/z, found 
380.3588 m/z. 
 
3,5-Dichlorobenzyl ((3S)-3-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamido)cyclopentyl)carbamate (18). Prepared according to General Procedure E 
with ursodeoxycholic acid (200 mg, 0.51 mmol, 1.1 equiv), N,N-diisopropylethylamine (330 
µL, 0.19 mmol, 4.0 equiv), HATU (194 mg, 0.51 mmol, 1.1 equiv), 3,5-dichlorobenzyl 3,5-
dichlorobenzyl (S)-3-aminopyrrolidine-1-carboxylate (136 mg, 0.47 mmol, 1.0 equiv) and 
DMF (10 mL). The crude material was subjected to the purification outlined in the General 
Procedure (silica gel, 0-10% MeOH in CH2Cl2) to afford the desired product as a clear solid 
(54 mg, 17%). Xmax (neat): 3450, 3415, 3030, 3963, 2940, 2862, 1725, 1637 cm-1. 1H NMR 
(CDCl3, 400 MHz): G 7.32-7.29 (m, 1H), 7.25-7.21 (m, 2H), 5.91 (s, 1H), 5.04 (s, 2H), 4.46 
(m, 1H), 372-3.61 (m, 3H), 3.62-3.54 (m, 2H), 3.54-3.46 (m, 2H), 3.25 (t, J = 12.1 Hz, 1H), 
2.25-2.12 (m, 2H), 2.10-2.01 (m, 1H), 2.02-1.96 (m, 1H), 1.83-1.73 (m, 5H), 1.69-1. 62 (m, 
2H), 1.60-1.53 (m, 2H), 1.50-1.37 (m, 5H), 1.25-1.18 (m, 8H), 1.14-0.97 (m, 3H), 0.96-0.86 
(m, 6H), 0.65 (s, 3H). 13C NMR (CDCl3, 101 MHz): G 173.7, 154.5, 140.2, 135.2, 128.3, 
126.2, 71.4, 65.4, 58.5, 55.9, 55.1, 51.7, 49.5, 48.7, 44.6, 44.2, 43.9, 42.6, 40.3, 39.4, 38.7, 
37.4, 37.1, 35.5, 35.0, 34.2, 33.5, 32.0, 31.8, 30.9, 30.4, 28.8, 27.0, 23.5, 21.3, 18.6, 18.5, 
12.2. Rotameric mixture observed. HRMS: exact mass calculated for [M+Na]+ 
(C36H52Cl2N2NaO5) requires 685.3145 m/z, found 685.3129 m/z. 
 
3,5-Dichlorobenzyl ((3R)-1-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)pyrrolidin-3-
yl)carbamate (19). Prepared according to General Procedure E with ursodeoxycholic acid 
(149 mg, 0.38 mmol, 1.1 equiv), N,N-diisopropylethylamine (306 µL, 1.75 mmol, 5.0 equiv), 
HATU (145 mg, 0.38 mmol, 1.1 equiv), 3,5-dichlorobenzyl (R)-pyrrolidin-3-ylcarbamate (100 
mg, 0.35 mmol, 1.0 equiv) and DMF (10 mL). The crude material was subjected to the 
purification outlined in the General Procedure (silica gel, 0-10% MeOH in CH2Cl2) to afford 
the desired product as a clear solid (36 mg, 15%). Xmax (neat): 3298, 2933, 2868, 1706, 1624, 
1436 cm-1. 1H NMR (CDCl3, 500 MHz): G 7.33-7.30 (m, 1H), 7.24-7.21 (m, 2H), 5.07-5.02 (m, 
2H), 5.02-4.97 (m, 1H), 4.36-4.21 (m, 1H), 3.78-3.65 (m, 1H), 3.62-3.50 (m, 4H), 3.45-3.31 
(m, 1H), 2.33-2.22 (m, 1H), 2.22-2.09 (m, 1H), 2.04-1.97 (m, 1H), 1.93-1.86 (m, 1H), 1.85-
1.75 (m, 4H), 1.71-1.63 (m, 2H), 1.63-1.55 (m, 4H), 1.53-1.47 (m, 2H), 1.47-1.41 (m, 4H), 
1.39-1.18 (m, 6H), 1.17-0.98 (m, 3H), 0.97-0.90 (m, 6H), 0.67 (s, 3H). NH not observed. 13C 
NMR (CDCl3, 101 MHz): G 172.8, 172.7, 155.6, 155.5, 139.9, 139.8, 135.24, 135.20, 128.4, 
128.3, 126.23, 126.20, 71.5, 71.4, 65.22, 65.15, 55.9, 55.1, 52.5, 51.5, 51.0, 50.8, 50.0, 44.7, 
43.85, 43.82, 43.78, 42.6, 40.3, 39.3, 37.4, 37.1, 35.6, 35.5, 35.1, 34.2, 32.4, 31.8, 31.4, 
31.0, 30.4, 28.82, 28.78, 27.0, 23.5, 21.3, 18.7, 12.3. Rotameric mixture observed. HRMS: 
exact mass calculated for [M+H]+ (C36H53Cl2N2O5) requires 663.3326 m/z, found 663.3323 
m/z. 
 3,5-Dichlorobenzyl ((3S)-1-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)pyrrolidin-3-
yl)carbamate (20). Prepared according to General Procedure E with ursodeoxycholic acid 
(200 mg, 0.51 mmol, 1.1 equiv), N,N-diisopropylethylamine (330 µL, 0.19 mmol, 4.0 equiv), 
HATU (194 mg, 0.51 mmol, 1.1 equiv), 3,5-dichlorobenzyl 3,5-dichlorobenzyl (S)-pyrrolidin-
3-ylcarbamate (136 mg, 0.47 mmol, 1.0 equiv) and DMF (10 mL The crude material was 
subjected to the purification outlined in the General Procedure (silica gel, 0-10% MeOH in 
CH2Cl2) to afford the desired product as a clear solid (56 mg, 18%). Xmax (neat): 3294, 2931, 
2866, 1708, 1626, 1436 cm-1. 1H NMR (CDCl3, 500 MHz): G 7.32-7.29 (m, 1H), 7.26-7.21 (m, 
2H), 5.08-5.02 (m, 2H), 4.34-4.20 (m, 1H), 3.77-3.65 (m, 1H), 3.65-3.48 (m, 4H), 3.45-3.29 
(m, 1H), 2.33-2.23 (m, 1H), 2.20-2.11 (m, 1H), 2.06-1.97 (m, 1H), 1.95-1.87 (m, 1H), 1.84-
1.74 (m, 4H), 1.71-1.64 (m, 2H), 1.62-1.53 (m, 5H), 1.52-1.41 (m, 6H), 1.37-1.30 (m, 2H), 
1.30-1.21 (m, 4H),  1.17-1.11 (m, 1H),  1.09-0.98 (m, 2H), 0.97-0.91 (m, 6H), 0.67 (d, J = 2.0 
Hz, 3H). 13C NMR (CDCl3, 101 MHz): G 172.8, 172.7, 155.4, 139.8, 139.7, 135.3, 128.5, 
126.3, 71.6, 71.5, 65.3, 55.9, 55.1, 52.6, 51.5, 51.1, 50.0, 44.6, 43.9, 43.8, 42.6, 40.3, 39.3, 
37.5, 37.0, 35.6, 35.1, 34.2, 32.5, 31.8, 31.4, 31.0, 30.5, 29.8, 28.8, 27.1, 23.5, 21.3, 18.8, 
12.3.  Rotameric mixture observed. HRMS: exact mass calculated for [M+Na]+ 
(C36H52Cl2N2NaO5) requires 685.3145 m/z, found 685.3113 m/z. 
Protein production and crystallization. ATX from rat was produced in HEK293 Flp-In cells 
as described previously.16 For co-crystallization of rATX with 3, 11, 5, and 17, rATX (3.5 mg 
mLí1) was first mixed in 10 molar excess with the compound and incubated for 30 min. In all 
cases, the best crystals were obtained at room temperature (293 K) in a 24-well optimization 
screen (18-20% PEG 3350, 0.1-0.4 M NaSCN and 0.1-0.4 M NH4, E\ PL[LQJ  ȝL of 
SURWHLQFRPSRXQG VROXWLRQ DQG  ȝL of reservoir solution. All crystals were vitrified in 
cryoprotectant, which consisted of reservoir solution with the addition of 20% (v/v) glycerol. 
Crystallographic data and methods. The X-ray diffraction data for the ATX-inhibitor 
complexes were collected at SLS on beamlines PXIII (3, 11, and 5) and PXI (17) at 100K. 
The crystallographic diffraction data for the ATX-inhibitor complexes were recorded on a 
PILATUS 2M-F detector for 3, 11, and 5 to a resolution of 1.95, 2.4, and 2.1 Å, respectively 
and on the EIGER 16M detector for 17 to 2.1 Å. All data were processed and integrated with 
XDS.17 17 was processed on site using the SLS automated processing pipeline and scaled 
with AIMLESS.18 The structures were determined by molecular replacement using 
PHASER19 with the structure of ATX (PDB entry 2XR9) as the search model. Model building 
and subsequent refinement were performed iteratively with COOT20 REFMAC521 and 
PDB_REDO.22 Structure validation was carried out by MolProbity. The structure models and 
experimental diffraction data were deposited at the PDB under codes 5MOS, 5MOM, 5MOD, 
5MOE). Crystallographic data and refinement details are available in Table 2. 
  
  
 
Table 2. Crystallography Details 
 
 3 5 11 17 
Data Collection     
Wavelength (Å) 1.0000 0.9801 0.9801 1.0000 
Resolution (Å) 1.95 2.4 2.1 2.1 
Space Group P 1  P 1 21 1 P 1 21 1 P 1 21 1 
Unit Cell a, b, c (Å) 
ĮȕȖ  (Ƞ)             
53.6, 61.7, 63.7 
103, 98, 93 
62.9, 88.0,77.4 
Į ȕ Ȗ            
62.8, 88.9, 77.3 
Į ȕ Ȗ            
62.9, 89.3, 77.2 
Į ȕ Ȗ             
CC1/2  0.996 (0.481) 0.998 (0.677) 0.998 (0.568) 0.998 (0.487) 
Rmerge 0.044 (0.812) 0.025 (0.921) 0.027 (1.148) 0.026 (0.766) 
,ı, 18.9 (1.5) 41.9 (1.6) 32.6 (1.2) 19.1 (1.6) 
Completeness (%) 98.8 (96.6) 98.3 (99.6) 97.1 (97.9) 89.2 (95.4) 
Redundancy 3.9 (3.8) 4.5 (4.5) 3.8 (4.0) 27 (2.5) 
Refinement     
No. atoms 6700 6451 6592 6598 
     Protein 6275 6251 6275 6242 
     Ligand/Metal/Glycan 186 172 215 256 
     Water/Iodine 239 28 102 100 
TLS groups 1 1 1 1 
Rwork/Rfree (%) 18.1/22.3 22.4/27.0 23.8/28.6 20.1/24.9 
Validation     
Rmsd/rmsZ bond lengths (Å) 0.012 0.008 0.007 0.011 
Rmsd/rmsZ bond angles (Ƞ) 1.631 1.377 1.249 1.515 
Ramachandran 
Preferred/ outliers  
98/0 95/0 97/0 96/0 
Sidechain rotamers Preferred 94 94 96 95 
MolProbity/Clash score (%ile) 100/100 100/100 100/100 100/100 
High Resolution shell in parentheses 
 
 
 
  
Biochemical assays and modeling of kinetic data. ATX lysoPLD activity was measured 
by choline release from LPC.23 20 nM human ATX (prepared from HEK 293 Flp-In cells) was 
incubated 150 mM LPC (18:1) in a final volume of 100 ȝL buffer containing 50 mM Tris, pH 
7.4, 0.01% Triton X-100, 50 mM CaCl2, 1 U mL-1 horseradish peroxidase, 2 mM homovanilic 
acid (HVA). The relative amount of released choline was measured by HVA fluorescence in 
a 96-well plate (Corning). Fluorescence intensity was determined at ex/em 320/450 nm 
every 30 s for 90 min with a Fluorostart plate reader (BMG Labtech). Data analysis was 
performed using GraphPad Prism. The experiments for determining IC50 values for the 
different inhibitors were performed by serial threefold dilutions; for each inhibitor 
concentration, the velocity of the reaction was monitored as a function of time in the lysoPLD 
assay as described above. The linear part of the reaction velocity was visually estimated 
(typically between 15 min and 60 min) and the observed fluorescence signal (described 
above) as a function of time was modeled for all inhibitor concentrations simultaneously 
using the formula:  ܨ௧ ൌ ܨ଴ ൅ ൬ ݒ௠௔௫ െ ݒ௠௜௡ሺͳ ൅ ܥ௜௡௛ ܫܥହ଴Τ ሻ ൅ ݒ௠௜௡൰ ݐ 
where Ft is the observed fluorescence signal relative to the choline product at each 
measurement, vmax and vmin are the fitted values for the minimum and maximum relative 
velocity and cinh is the corresponding inhibitor concentration.  To identify the mode of 
inhibition of ATX by 17, we used regression analysis tools within the GraphPad Prism 
software to determine WKHYDOXHRIĮXVLQJWKHEXLOW-in formula for the mixed inhibition model. 
The values of all derived parameters indicate mean values as obtained by nonlinear 
regression analysis; triplicate data were used as separate observations during the fit; ± 
values indicate the standard error of the mean. 
Cell-based assays. BJEH fibroblasts were seeded in 6-well tissue culture plates in DMEM 
(GIBCO, Life Technologies) containing 10% FCS (Hyclone, Thermo Scientific), 2 mM 
glutamine, 100 UmL-1 penicillin and 100 mgmL-1 streptomycin (GIBCO, Life Technologies). 
When ± 60-90 confluent, they were serum starved (DMEM with glutamine and pen/strep, 
without FCS) for 16 hours. hATX (10 nM final concentration) was incubated with inhibitor for 
30 min in serum free medium (total volume 1 mL). Medium from the 6-well plates was 
removed and replaced with 1 mL of ATX-inhibitor (17) mixture. Cells were stimulated for 15 
min, medium was removed and plates were immediately frozen on dry ice and stored at -
80 °C. Cells were lysed in the plates on ice for ± 10 min (lysis buffer: RIPA, containing 
sodium fluoride, orthovanadate and protease inhibitors). Lysates were centrifuged for 30 
minutes at 10.000 rpm to remove cell debris and were taken up in loading buffer containing 
DTT and boiled for 10 min at 95°C. Samples were loaded on a pre-cast gel (Bis-Tris 
Invitrogen 4-12%) and separated by gel electrophoresis. The gel was transferred by western 
blotting to a nitrocellulose membrane which was blocked in milk (to reduce non-specific 
binding) before the membrane was probed with the desired primary antibodies overnight (in 
this case p-AKT and total AKT). The membrane was washed 3 × in PBS-tween and probed 
with a HRP-conjugated anti-Rabbit antibody for 1 hour. Washed 3 × and developed using 
ECL reagent using a BioRad chemidoc imaging system. 
Mouse experiments. ATX inhibitors were dissolved at 50 mgmL-1 in vehicle (Hydroxypropyl 
Cellulose 2% / Tween 80 0.1%) and administered intraperitoneally at 10 mgkg-1.  Blood was 
collected after 8 hours, plasma isolated and levels of 8 abundant LPA species determined by 
HPLC electrospray ionization tandem mass spectrometry as reported previously.15 Protocols 
and procedures for animal studies conformed to current US Public Health Service policy and 
were reviewed and approved by the Institutional Animal Care and Use Committee at the 
University of Kentucky.  
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